Sovaldi

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
22-08-2022
Produktens egenskaper Produktens egenskaper (SPC)
22-08-2022

Aktiva substanser:

Sofosbuvir

Tillgänglig från:

Gilead Sciences Ireland UC

ATC-kod:

J05AX15

INN (International namn):

sofosbuvir

Terapeutisk grupp:

Antivirals for systemic use

Terapiområde:

Hepatitis C, Chronic

Terapeutiska indikationer:

Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.

Produktsammanfattning:

Revision: 28

Bemyndigande status:

Authorised

Tillstånd datum:

2014-01-16

Bipacksedel

                                79
B. PACKAGE LEAFLET
80
PACKAGE LEAFLET: INFORMATION FOR THE USER
SOVALDI 400 MG FILM-COATED TABLETS
SOVALDI 200 MG FILM-COATED TABLETS
sofosbuvir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sovaldi is and what it is used for
2.
What you need to know before you take Sovaldi
3.
How to take Sovaldi
4.
Possible side effects
5.
How to store Sovaldi
6.
Contents of the pack and other information
IF SOVALDI HAS BEEN PRESCRIBED FOR YOUR CHILD, PLEASE NOTE THAT ALL
THE INFORMATION IN THIS LEAFLET IS
APPLICABLE TO YOUR CHILD (IN THIS CASE PLEASE READ “YOUR CHILD”
INSTEAD OF “YOU”).
1.
WHAT SOVALDI IS AND WHAT IT IS USED FOR
Sovaldi contains the active substance sofosbuvir which is given to
treat hepatitis C virus infection in
adults and children 3 years of age and older.
Hepatitis C is a virus that infects the liver. This medicine works by
lowering the amount of hepatitis C
virus in your body and removing the virus from your blood over a
period of time.
Sovaldi is always taken with other medicines to treat hepatitis C. It
will not work on its own. It is
commonly taken with either:
•
Ribavirin (children and adult patients), or
•
Peginterferon alfa and ribavirin (adult patients)
It is very important that you also read the leaflets for the other
medicines that you will be taking with
Sovaldi. If you have any questions about your medicines, please ask
your doctor or pharmacist.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE SOVALDI
DO NOT TAKE SOVALDI
•
If you are allergic to sofosbuvir or
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sovaldi 400 mg film-coated tablets
Sovaldi 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sovaldi 400 mg film-coated tablets
Each film-coated tablet contains 400 mg of sofosbuvir.
Sovaldi 200 mg film-coated tablets
Each film-coated tablet contains 200 mg of sofosbuvir.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Sovaldi 400 mg film-coated tablets
Yellow, capsule-shaped, film-coated tablet of dimensions of
approximately 20 mm x 9 mm, debossed
on one side with “GSI” and “7977” on the other side.
Sovaldi 200 mg film-coated tablets
Yellow, oval-shaped, film-coated tablet of dimensions of approximately
15 mm x 8 mm, debossed on
one side with “GSI” and “200” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Sovaldi is indicated in combination with other medicinal products for
the treatment of chronic
hepatitis C (CHC) in adults and paediatric patients aged 3 years and
above (see sections 4.2, 4.4 and
5.1).
For hepatitis C virus (HCV) genotype specific activity, see sections
4.4 and 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Sovaldi treatment should be initiated and monitored by a physician
experienced in the management of
patients with CHC.
Posology
The recommended dose of Sovaldi in adults is one 400 mg tablet, taken
orally, once daily with food
(see section 5.2).
The recommended dose of Sovaldi in paediatric patients aged 3 years
and above is based on weight (as
detailed in Table 2). Sovaldi should be taken with food (see section
5.2).
3
Sovaldi oral granules are available for the treatment of chronic
HCV-infection in paediatric patients
aged 3 years and above having difficulty in swallowing film-coated
tablets. Please refer to the
Summary of Product Characteristics for Sovaldi 150 mg or 200 mg
granules.
Sovaldi should be used in combination with other medicinal products.
Monotherapy of Sovaldi is not
recommended (see section 
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 22-08-2022
Produktens egenskaper Produktens egenskaper bulgariska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 14-08-2020
Bipacksedel Bipacksedel spanska 22-08-2022
Produktens egenskaper Produktens egenskaper spanska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 14-08-2020
Bipacksedel Bipacksedel tjeckiska 22-08-2022
Produktens egenskaper Produktens egenskaper tjeckiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 14-08-2020
Bipacksedel Bipacksedel danska 22-08-2022
Produktens egenskaper Produktens egenskaper danska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 14-08-2020
Bipacksedel Bipacksedel tyska 22-08-2022
Produktens egenskaper Produktens egenskaper tyska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 14-08-2020
Bipacksedel Bipacksedel estniska 22-08-2022
Produktens egenskaper Produktens egenskaper estniska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 14-08-2020
Bipacksedel Bipacksedel grekiska 22-08-2022
Produktens egenskaper Produktens egenskaper grekiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 14-08-2020
Bipacksedel Bipacksedel franska 22-08-2022
Produktens egenskaper Produktens egenskaper franska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 14-08-2020
Bipacksedel Bipacksedel italienska 22-08-2022
Produktens egenskaper Produktens egenskaper italienska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 14-08-2020
Bipacksedel Bipacksedel lettiska 22-08-2022
Produktens egenskaper Produktens egenskaper lettiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 14-08-2020
Bipacksedel Bipacksedel litauiska 22-08-2022
Produktens egenskaper Produktens egenskaper litauiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 14-08-2020
Bipacksedel Bipacksedel ungerska 22-08-2022
Produktens egenskaper Produktens egenskaper ungerska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 14-08-2020
Bipacksedel Bipacksedel maltesiska 22-08-2022
Produktens egenskaper Produktens egenskaper maltesiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 14-08-2020
Bipacksedel Bipacksedel nederländska 22-08-2022
Produktens egenskaper Produktens egenskaper nederländska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 14-08-2020
Bipacksedel Bipacksedel polska 22-08-2022
Produktens egenskaper Produktens egenskaper polska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 14-08-2020
Bipacksedel Bipacksedel portugisiska 22-08-2022
Produktens egenskaper Produktens egenskaper portugisiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 14-08-2020
Bipacksedel Bipacksedel rumänska 22-08-2022
Produktens egenskaper Produktens egenskaper rumänska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 14-08-2020
Bipacksedel Bipacksedel slovakiska 22-08-2022
Produktens egenskaper Produktens egenskaper slovakiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 14-08-2020
Bipacksedel Bipacksedel slovenska 22-08-2022
Produktens egenskaper Produktens egenskaper slovenska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 14-08-2020
Bipacksedel Bipacksedel finska 22-08-2022
Produktens egenskaper Produktens egenskaper finska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 14-08-2020
Bipacksedel Bipacksedel svenska 22-08-2022
Produktens egenskaper Produktens egenskaper svenska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 14-08-2020
Bipacksedel Bipacksedel norska 22-08-2022
Produktens egenskaper Produktens egenskaper norska 22-08-2022
Bipacksedel Bipacksedel isländska 22-08-2022
Produktens egenskaper Produktens egenskaper isländska 22-08-2022
Bipacksedel Bipacksedel kroatiska 22-08-2022
Produktens egenskaper Produktens egenskaper kroatiska 22-08-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 14-08-2020

Sök varningar relaterade till denna produkt

Visa dokumenthistorik